###begin article-title 0
###xml 191 213 191 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 191 212 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 35 57 35 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 82 92 82 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 582 592 582 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 35 56 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 82 91 <span type="species:ncbi:1280">S. aureus</span>
###xml 93 97 <span type="species:ncbi:1280">VISA</span>
###xml 110 114 <span type="species:ncbi:1280">VISA</span>
###xml 582 591 <span type="species:ncbi:1280">S. aureus</span>
###xml 593 597 <span type="species:ncbi:1280">VSSA</span>
###xml 609 613 <span type="species:ncbi:1280">VISA</span>
###xml 633 637 <span type="species:ncbi:1280">VSSA</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
###xml 734 738 <span type="species:ncbi:1280">VISA</span>
###xml 862 866 <span type="species:ncbi:1280">VSSA</span>
###xml 877 881 <span type="species:ncbi:1280">VISA</span>
Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed vancomycin therapy. Up-regulation of genes associated with the "cell wall stimulon" and mutations in the vraSR operon have both been implicated in the development of resistance, however the molecular mechanisms of resistance are not completely understood. To further elucidate the mechanisms leading to resistance transcriptome comparisons were performed using multiple clinical pairs of vancomycin-susceptible S. aureus (VSSA) and hVISA/VISA (n = 5), and three VSSA control pairs from hospitalized patients with persistent bacteraemia that did not develop hVISA/VISA. Based on the transcriptome results multiple genes were sequenced and innate immune system stimulation was assessed in the VSSA and hVISA/VISA pairs.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraS </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR</italic>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">saeSR</italic>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mgrA</italic>
###xml 276 279 276 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rot</italic>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">merR </italic>
###xml 224 228 <span type="species:ncbi:1280">VISA</span>
###xml 367 371 <span type="species:ncbi:1280">VSSA</span>
###xml 382 386 <span type="species:ncbi:1280">VISA</span>
###xml 570 574 <span type="species:ncbi:1280">VISA</span>
###xml 872 876 <span type="species:ncbi:1280">VISA</span>
Here we show that up-regulation of vraS and the "cell wall stimulon" is not essential for acquisition of low-level vancomycin resistance and that different transcriptional responses occur, even between closely related hVISA/VISA strains. DNA sequencing of vraSR, saeSR, mgrA, rot, and merR regulatory genes and upstream regions did not reveal any differences between VSSA and hVISA/VISA despite transcriptional changes suggesting mutations in these loci may be linked to resistance in these strains. Enhanced capsule production and reduced protein A expression in hVISA/VISA were confirmed by independent bioassays and fully supported the transcriptome data. None of these changes were observed in the three control pairs that remained vancomycin-susceptible during persistent bacteremia. In a macrophage model of infection the changes in cell surface structures in hVISA/VISA strains were associated with significantly reduced NF-kappaB activation resulting in reduced TNF-alpha and IL-1beta expression.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 83 92 83 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 83 92 <span type="species:ncbi:1280">S. aureus</span>
###xml 247 251 <span type="species:ncbi:1280">VISA</span>
We conclude that there are multiple pathways to low-level vancomycin resistance in S. aureus, even among closely related clinical strains, and these can result in an attenuated host immune response. The persistent infections associated with hVISA/VISA strains may be a consequence of changes in host pathogen interactions in addition to the reduced antibiotic susceptibility.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 35 57 35 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 82 92 82 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 35 56 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 82 91 <span type="species:ncbi:1280">S. aureus</span>
###xml 93 97 <span type="species:ncbi:1280">VISA</span>
###xml 117 121 <span type="species:ncbi:1280">VISA</span>
###xml 243 247 <span type="species:ncbi:1280">VISA</span>
Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus [VISA], and heterogenous-VISA [hVISA]) is associated with vancomycin treatment failure and persistent infection [1-4]. The mechanisms underlying hVISA/VISA appear to involve step-wise processes under vancomycin selective pressure [5,6]. Global metabolic changes affecting the synthesis and structure of the bacterial cell wall are the major phenotypic features. These include cell wall thickening [7-9] associated with increased production of abnormal muropeptides [10], increased D-ala-D-ala residues and reduced peptidoglycan cross-linking [11], reduced growth rate, and reduced autolytic activity [8,11,12]. The thickened cell wall that results is thought to prevent diffusion of vancomycin to its active site in the cytoplasmic membrane [13].
###end p 9
###begin p 10
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR</italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 752 758 752 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 779 780 779 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 819 822 819 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr</italic>
###xml 880 889 880 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1017 1018 1017 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1279 1281 1279 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1330 1339 1330 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1342 1350 1342 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1782 1784 1782 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1785 1787 1785 1787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1788 1790 1788 1790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 122 126 <span type="species:ncbi:1280">VISA</span>
###xml 343 347 <span type="species:ncbi:1280">VISA</span>
###xml 612 619 <span type="species:ncbi:9606">patient</span>
###xml 681 685 <span type="species:ncbi:1280">VISA</span>
###xml 880 889 <span type="species:ncbi:1280">S. aureus</span>
###xml 930 934 <span type="species:ncbi:1280">VISA</span>
###xml 1129 1133 <span type="species:ncbi:1280">VISA</span>
###xml 1438 1444 <span type="species:ncbi:9606">humans</span>
###xml 1539 1543 <span type="species:ncbi:1280">VISA</span>
###xml 1711 1715 <span type="species:ncbi:1280">VISA</span>
The two-component regulatory system vraSR, was shown to be up-regulated in the Japanese strains Mu50 and Mu3 [14] and the VISA strain JH9 [15]. vraSR is a part of the "cell wall stimulon" that positively modulates cell wall biosynthesis, is induced by cell wall active agents [16,17], and has been suggested to be consistently up-regulated in VISA strains [15,18]. It is postulated that the cell wall active glycopeptides stimulate the over expression of the "cell wall stimulon" and promote resistance by increasing cell wall thickness. Recently, the complete genome sequencing of an isolate pair from a single patient demonstrated a small number of mutations associated with the VISA phenotype. Early in the evolution of resistance a mutation in the vraSR operon was detected [6]. Point mutations and inactivation of agr, an important quorum sensing global regulatory system in S. aureus, have been previously described in some VISA strains [19], and were associated with higher levels of resistance in strain JH9 [6], but are not a consistent finding. Recently, a number of additional genes were found to be over expressed in VISA strains and selective over-expression of these genes in the vancomycin susceptible strain N315 led to subtle increases in vancomycin resistance [20]. Most studies to date have been performed with in vitro or in vivo laboratory derived strains and the relevance of these findings to clinical infection in humans is unclear. A major limitation of previous studies assessing transcriptional changes in hVISA/VISA strains is that only single pairs of isolates have been used. This has made it difficult to draw conclusions about the relevance of the transcriptional differences in VISA strains as often hundreds of genes were differentially regulated [15,17,21].
###end p 10
###begin p 11
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 49 53 <span type="species:ncbi:1280">VSSA</span>
###xml 64 68 <span type="species:ncbi:1280">VISA</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 109 113 <span type="species:ncbi:1280">MRSA</span>
###xml 244 248 <span type="species:ncbi:1280">VISA</span>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
###xml 572 576 <span type="species:ncbi:1280">MRSA</span>
###xml 766 770 <span type="species:ncbi:1280">VSSA</span>
###xml 781 785 <span type="species:ncbi:1280">VISA</span>
###xml 889 893 <span type="species:ncbi:1280">MRSA</span>
###xml 993 997 <span type="species:ncbi:1280">VISA</span>
###xml 1046 1054 <span type="species:ncbi:9606">patients</span>
###xml 1075 1079 <span type="species:ncbi:1280">VISA</span>
###xml 1190 1194 <span type="species:ncbi:1280">VISA</span>
###xml 1222 1226 <span type="species:ncbi:1280">VISA</span>
###xml 1227 1231 <span type="species:ncbi:1280">VISA</span>
We recently characterized five clinical pairs of VSSA and hVISA/VISA, isolated from patients with persistent MRSA bacteremia, and in whom vancomycin treatment failed [12]. These isolates demonstrated phenotypic changes commonly associated with VISA strains, including cell wall thickening and reduced autolytic activity. The level of resistance demonstrated in these strains is more frequently found clinically, as strains with a vancomycin MIC of >/= 8 mg/L are still uncommon. In addition, we have obtained three pairs of clinical isolates from patients with persistent MRSA bacteremia and vancomycin treatment failure, in whom low-level vancomycin resistance did not develop. We used microarray analysis to investigate the transcriptional differences in the five VSSA and hVISA/VISA pairs and the three control pairs to determine if consistent transcriptional changes occur in clinical MRSA isolates associated with persistent bacteraemia and a common level of vancomycin resistance (hVISA/VISA with vancomycin MICs of 2-4 mg/L). Because many patients infected with hVISA/VISA strains have persistent infection, and because of the significant changes in surface structure of these hVISA/VISA strains, the impact of the VISA/VISA phenotype on host-pathogen interactions was also assessed.
###end p 11
###begin p 12
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 231 235 <span type="species:ncbi:1280">VISA</span>
###xml 307 311 <span type="species:ncbi:1280">VISA</span>
###xml 435 439 <span type="species:ncbi:1280">VISA</span>
Here we demonstrate that transcriptome patterns are divergent in different isolates pairs, and up-regulation of the "cell wall stimulon" and mutations in vraSR are not essential for the expression of vancomycin resistance in hVISA/VISA isolates. In addition we demonstrate for the first time that the hVISA/VISA phenotype is associated with significant changes in the expression of capsule and protein A on the cell surface, and hVISA/VISA strains produce less innate immune system activation.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
Isolate characteristics
###end title 14
###begin p 15
###xml 656 660 656 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 758 762 758 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 928 929 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 5 9 <span type="species:ncbi:1280">VSSA</span>
###xml 20 24 <span type="species:ncbi:1280">VISA</span>
###xml 236 240 <span type="species:ncbi:1280">MRSA</span>
###xml 296 300 <span type="species:ncbi:1280">VISA</span>
###xml 398 402 <span type="species:ncbi:1280">VSSA</span>
###xml 413 417 <span type="species:ncbi:1280">VISA</span>
Five VSSA and hVISA/VISA isolate pairs (pairs 1 to 5) were included in this study as well as 3 control pairs of strains (pairs 6 to 8). The reason for including the control pairs was to determine if transcriptional changes are found in MRSA isolates after persistent bacteraemia, but where hVISA/VISA does not develop. If similar transcriptional changes were found in the control strains as in the VSSA and hVISA/VISA pairs it would suggest these changes were independent of the resistance mechanism. In the three control pairs (pairs 6 to 8) pulsed field gel electrophoresis (PFGE) demonstrated identical banding patterns for isolate pairs, and identical spa types (JKD6084 and JKD6089, spa type 382; JKD6090 and JKD6094, spa type 382; JKD6095 and JKD6097, spa type 3). All 6 control isolates were fully vancomycin susceptible by population analysis profile testing, and had vancomycin MICs within the susceptible range (Table 1).
###end p 15
###begin p 16
Study isolates and susceptibility results
###end p 16
###begin p 17
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 30 39 30 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 71 80 71 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 30 39 <span type="species:ncbi:1280">S. aureus</span>
###xml 41 45 <span type="species:ncbi:1280">VISA</span>
###xml 71 80 <span type="species:ncbi:1280">S. aureus</span>
###xml 96 100 <span type="species:ncbi:1280">VISA</span>
aVSSA, vancomycin-susceptible S. aureus; VISA, vancomycin-intermediate S. aureus; hVISA, hetero-VISA.
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bMinimum inhibitory concentration. VCM, vancomycin; TEIC, teicoplanin.
###end p 18
###begin title 19
Microarray analysis of control pairs
###end title 19
###begin p 20
No genes were differentially expressed in pairs 7 and 8 when the later clinical isolate (JKD6094 and JKD6097) were compared to the earlier isolate (JKD6090 and JKD6095). For isolate pair 6 only two genes were differentially expressed; SACOL0935 (D-alanine-activating enzyme/D-alanine-D-alanyl carrier protein ligase), fold ratio 2.32; and SACOL0936 (DltB, a putative activated D-alanine membrane transport protein), fold ratio 2.27.
###end p 20
###begin title 21
###xml 38 42 <span type="species:ncbi:1280">VISA</span>
Microarray analysis of clinical hVISA/VISA strains
###end title 21
###begin p 22
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agrA</italic>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agrB</italic>
###xml 869 872 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa</italic>
###xml 874 878 874 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fnbA</italic>
###xml 880 884 880 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fnbB</italic>
###xml 886 889 886 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">efb</italic>
###xml 1055 1059 1055 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 8 12 <span type="species:ncbi:1280">VSSA</span>
###xml 23 27 <span type="species:ncbi:1280">VISA</span>
###xml 168 172 <span type="species:ncbi:1280">VISA</span>
###xml 197 201 <span type="species:ncbi:1280">VSSA</span>
###xml 1117 1121 <span type="species:ncbi:1280">VISA</span>
For the VSSA and hVISA/VISA pairs a list of genes of interest was generated as described in the methods section. These results are presented as the fold ratio of hVISA/VISA compared to the related VSSA isolate. There were 54 genes that were down-regulated, and 89 genes that were up-regulated in at least two isolate pairs. Selected genes from this list which were of particular interest are highlighted in figure 1 and additional file 1. The complete gene list is also provided in additional file 2. Down-regulation of the quorum sensing global regulator agr (agrA, agrB) was prominent across three pairs. This would be expected to have secondary effects on exotoxin production and expression of cell adhesion molecules, and a number of genes involved in pathogenesis and toxin production, and cell surface adhesion molecules were indeed significantly down-regulated (spa, fnbA, fnbB, efb, putative exotoxin SACOL0478, fibrinogen-binding protein related proteins and precursors SACOL1164 and SACOL1169). Of particular note, marked down-regulation of the spa gene SACOL0095 was demonstrated in four of the five hVISA/VISA isolates, and another IgG-binding protein, SACOL2418 was down-regulated in all five isolates.
###end p 22
###begin p 23
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Heat map analysis of selected genes</bold>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 207 211 <span type="species:ncbi:1280">VISA</span>
###xml 224 228 <span type="species:ncbi:1280">VSSA</span>
Heat map analysis of selected genes. Heat map analysis of selected genes which were differentially expressed in at least 2 isolate pairs. The results are expressed as fold ratio of gene expression for hVISA/VISA compared to VSSA. Results are presented for all 5 isolate pairs without antibiotic exposure and all 5 isolate pairs after exposure to vancomycin. This figure shows the upper quartile of these selected genes, for the full image please see additional file 1.
###end p 23
###begin p 24
###xml 123 181 123 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ureA, ureB, ureC, ureD, ureE, ureF, ureG, narG, narH, nirD</italic>
###xml 226 229 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hom</italic>
###xml 231 258 231 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lysC, asd, dapA, dapB, dapD</italic>
###xml 334 356 334 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ilvB, ilvC, ilvE, leuA</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cap5A</italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cap5B</italic>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cap5D</italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cap5E</italic>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cap5F</italic>
###xml 649 652 649 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr</italic>
###xml 702 707 702 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">merR </italic>
###xml 507 511 <span type="species:ncbi:1280">VISA</span>
A number of contiguous genes were up-regulated. This included genes involved in urease production and nitrogen metabolism (ureA, ureB, ureC, ureD, ureE, ureF, ureG, narG, narH, nirD) and amino acid biosynthesis for aspartate (hom, lysC, asd, dapA, dapB, dapD). In addition genes encoding pyruvate biosynthesis were also up-regulated (ilvB, ilvC, ilvE, leuA). Of particular interest was the up-regulation of capsular polysaccharide biosynthesis genes (cap5A, cap5B, cap5D, cap5E, cap5F) in a number of hVISA/VISA isolates. The gene encoding the SceD protein (SACOL2088, a putative transglycosylase) was frequently up-regulated. Regulators other than agr, which had differential expression, included the merR family regulators SACOL2193 and SACOL2517 in 4 and 3 pairs respectively, the GntR family regulator (SACOL1997) in 2 pairs, and up-regulation of a putative regulatory gene (SACOL2585) in 2 pairs, but down-regulation in another pair.
###end p 24
###begin p 25
###xml 74 84 74 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 718 723 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">saeSR</italic>
###xml 74 83 <span type="species:ncbi:1280">S. aureus</span>
###xml 214 218 <span type="species:ncbi:1280">VISA</span>
###xml 397 401 <span type="species:ncbi:1280">VISA</span>
###xml 406 410 <span type="species:ncbi:1280">VSSA</span>
###xml 462 466 <span type="species:ncbi:1280">VSSA</span>
###xml 477 481 <span type="species:ncbi:1280">VISA</span>
###xml 905 909 <span type="species:ncbi:1280">VISA</span>
###xml 922 926 <span type="species:ncbi:1280">VSSA</span>
Previous studies have demonstrated significant transcriptional changes in S. aureus isolates when compared to non-exposed isolates, after exposure to vancomycin. We therefore exposed both the susceptible and hVISA/VISA isolate in pairs 1 to 5 to vancomycin for 30 min prior to RNA extraction and microarray analysis, in an effort to detect differences in responses to vancomycin exposure in hVISA/VISA and VSSA isolates from the same pair. After exposure of the VSSA and hVISA/VISA in each pair to vancomycin there was a more pronounced gene down-regulation compared to the initial analysis (Figure 1, and additional file 2). This included significant down-regulation across 3 of the 5 pairs in the 2-component system saeSR, and marked down-regulation of MW2407 encoding a hypothetical protein in multiple pairs, suggesting that vancomycin led to differential effects in gene regulation between the hVISA/VISA isolate and VSSA in each pair. There were however, no consistent effects of the vancomycin exposure across all isolate pairs.
###end p 25
###begin p 26
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 71 75 <span type="species:ncbi:1280">VSSA</span>
###xml 86 90 <span type="species:ncbi:1280">VISA</span>
###xml 497 501 <span type="species:ncbi:1280">VISA</span>
A heat map analysis was also performed to assess global changes in all VSSA and hVISA/VISA isolate pairs, using the complete microarray data sets. The heat map of all microarray data (additional file 3) demonstrates that although there are some consistent changes across a few of the isolate pairs (in a small subset of genes, such as genes encoding capsule production, protein A, and urease production), there are significant differences in the global transcriptional patterns in different hVISA/VISA isolates, such that the global transcriptional patterns were divergent between different isolate pairs.
###end p 26
###begin title 27
###xml 97 101 <span type="species:ncbi:1280">VISA</span>
Genes associated with the "cell wall stress stimulon" are not consistently up-regulated in hVISA/VISA
###end title 27
###begin p 28
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraS </italic>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 103 107 <span type="species:ncbi:1280">VISA</span>
Because of the recent interest in the importance of up-regulation of the "cell wall stimulon" in hVISA/VISA, linked with cell wall thickening and resistance, we specifically analyzed the transcriptional changes in these genes. Two isolates pairs demonstrated up-regulation of vraS and associated genes in the initial microarray analysis, but of particular interest was the lack of any significant change in two pairs (pair 1 and 5), and the down regulation in the another pair (pair 3) (Figure 2). After vancomycin exposure a number of these cell wall genes were also down regulated in pair 5 (SACOL1066, SACOL1943, SACOL1944, SACOL2116, SACOL2571).
###end p 28
###begin p 29
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Heat map analysis of cell wall genes</bold>
###xml 261 265 <span type="species:ncbi:1280">VISA</span>
###xml 278 282 <span type="species:ncbi:1280">VSSA</span>
Heat map analysis of cell wall genes. Heat map analysis of "core cell wall genes" and additional cell wall genes which have been commonly shown to be important in cell wall biosynthesis [56]. The results are expressed as fold ratio of gene expression for hVISA/VISA compared to VSSA. Results are presented for all 5 isolate pairs without antibiotic exposure and all 5 isolate pairs after exposure to vancomycin.
###end p 29
###begin title 30
Protein expression and capsule production correlate with array results
###end title 30
###begin p 31
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 321 324 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 537 542 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ureA </italic>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 917 918 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 72 76 <span type="species:ncbi:1280">VISA</span>
###xml 418 422 <span type="species:ncbi:1280">VISA</span>
###xml 448 452 <span type="species:ncbi:1280">VSSA</span>
###xml 980 984 <span type="species:ncbi:1280">VSSA</span>
To determine if the transcriptional changes that were detected in hVISA/VISA isolates resulted in changes in protein A and capsule production, as well as urease activity, expression was determined for all isolates. A significant decrease in protein A production was demonstrated for 4 of the 5 pairs (Figure 3). For the 5th pair, protein A production was low in both isolates. Urease activity was higher for the hVISA/VISA isolates compared to the VSSA isolates for 4 of the 5 pairs (Table 2). These results correlated well with spa and ureA gene expression (Table 2, Figure 3, additional file 2). A PCR was designed to determine the capsule genotype of isolates (capsule type 5 or capsule type 8). All isolates from pairs 1 to 5 were capsule type 8 strains by PCR. Capsule immunoblot confirmed the PCR capsule typing results, and demonstrated a significant increase in capsule expression in 4 of the 5 pairs (Figure 4). The last pair (no 5) had minimal capsule expression in the VSSA or hVISA strain, and these results also correlated well with microarray data.
###end p 31
###begin p 32
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Western blot analysis of protein A production</bold>
###xml 410 413 410 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa</italic>
###xml 105 109 <span type="species:ncbi:1280">VISA</span>
###xml 114 118 <span type="species:ncbi:1280">VSSA</span>
###xml 443 447 <span type="species:ncbi:1280">VISA</span>
###xml 452 456 <span type="species:ncbi:1280">VSSA</span>
Western blot analysis of protein A production. Analysis of protein A production by Western Blot in hVISA/VISA and VSSA pairs. A. Pair 1 (lane 1, JKD 6000; lane 2, JKD 6001), pair 2 (lane 3, JKD 6009; lane 4, JKD 6008), pair 3 (lane 5, JKD 6021; lane 6, JKD 6023), pair 4 (lane 7, JKD 6052, lane 8, JKD 6051), pair 5 (lane 9, JKD 6004; lane 10, JKD 6005). B. Fold ratios for protein A production and protein A (spa) gene expression for 5 hVISA/VISA and VSSA pairs.
###end p 32
###begin p 33
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Capsule immunoblot comparison of VSSA to hVISA/VISA</bold>
###xml 33 37 <span type="species:ncbi:1280">VSSA</span>
###xml 47 51 <span type="species:ncbi:1280">VISA</span>
Capsule immunoblot comparison of VSSA to hVISA/VISA. Capsule immuoblot using anti-capsule type 8 antibody. Serial 3-fold dilutions of crude capsule extracts were loaded onto nitrocellulose membrane. Positive control, capsule type 8 positive strain P1; negative control, capsule type 5 positive strain Newman.
###end p 33
###begin p 34
Urease assay results and comparison to microarray results
###end p 34
###begin p 35
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Abbreviations</bold>
###xml 44 53 44 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 85 94 85 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 15 19 <span type="species:ncbi:1280">VSSA</span>
###xml 44 53 <span type="species:ncbi:1280">S. aureus</span>
###xml 55 59 <span type="species:ncbi:1280">VISA</span>
###xml 85 94 <span type="species:ncbi:1280">S. aureus</span>
Abbreviations: VSSA, vancomycin-susceptible S. aureus; VISA, vancomycin intermediate S. aureus.
###end p 35
###begin p 36
*Microarray fold ratios were statistically significant.
###end p 36
###begin title 37
Sequencing of regulatory genes does not demonstrate mutations leading to altered regulatory gene expression
###end title 37
###begin p 38
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">saeSR </italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR</italic>
###xml 460 464 460 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">merR</italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mgrA </italic>
###xml 545 549 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rot </italic>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mgrA </italic>
###xml 732 741 732 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 830 833 830 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ot </italic>
###xml 838 843 838 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sarA </italic>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1247 1257 1247 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 97 101 <span type="species:ncbi:1280">VISA</span>
###xml 280 284 <span type="species:ncbi:1280">VSSA</span>
###xml 295 299 <span type="species:ncbi:1280">VISA</span>
###xml 348 352 <span type="species:ncbi:1280">VSSA</span>
###xml 363 367 <span type="species:ncbi:1280">VISA</span>
###xml 732 741 <span type="species:ncbi:1280">S. aureus</span>
###xml 1247 1256 <span type="species:ncbi:1280">S. aureus</span>
###xml 1458 1462 <span type="species:ncbi:1280">VSSA</span>
###xml 1473 1477 <span type="species:ncbi:1280">VISA</span>
In an effort to identify any genetic mutations leading to the resistant phenotype in the 5 hVISA/VISA strains, regulatory loci which were differentially expressed in the microarray experiments or which were predicted to be linked to the microarray results were sequenced in all 5 VSSA and hVISA/VISA pairs. We found no sequence changes between the VSSA and hVISA/VISA in each pair in the two-component regulators saeSR and vraSR, nor in the genes encoding the merR-like regulators SACOL2193 and SACOL2517. The regulatory genes mgrA (SA0641) and rot (repressor of toxins) were also sequenced. Although mgrA was not differentially expressed on the microarray results, it has recently been shown to be an important global regulator in S. aureus, with effects on autolytic activity, protein A expression and capsule production [22]. rot is a sarA homologue which is blocked by RNAIII [23,24]. It has effects on expression of multiple genes, including those involved in synthesis of urease, protein A, and ABC transporters [25]. Again, no mutations were found in either gene. Finally, because of the dramatic decrease in MW2407 expression in the vancomycin exposure experiments, the region MW2406 to MW2408 was sequenced (this gene on the TIGR version S. aureus array is unique to MW2). The expected product size based on the MW2 genome was 2898 bp, but the amplified fragment from our strains was ~1900 bp. There were no differences in the sequences between the VSSA and hVISA/VISA strains. The region amplified in our strains matched closely to 2 regions in MRSACOL encoding tandem lipoproteins and a hypothetical protein (SACOL2496, SACOL2498 and SACOL2492, SACOL2493).
###end p 38
###begin title 39
Increasing vancomycin resistance is associated with reduced NF-kappaB activation and reduced pro-inflammatory cytokine release
###end title 39
###begin p 40
###xml 326 327 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1017 1018 990 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 163 167 <span type="species:ncbi:1280">VISA</span>
###xml 206 210 <span type="species:ncbi:1280">VISA</span>
###xml 435 439 <span type="species:ncbi:1280">VISA</span>
###xml 474 478 <span type="species:ncbi:1280">VSSA</span>
Because we detected a number of significant changes in staphylococcal surface structures that interact with the innate immune system during the evolution of hVISA/VISA, we next wished to establish if hVISA/VISA displayed a decreased activation of the prototypic inflammatory transcription factor NF-kappaB. As shown in Figure 5, there was a statistically significant decrease in NF-kappaB activation demonstrated with 4 of the 5 hVISA/VISA isolates compared to their parent VSSA strain, particularly at lower concentrations. This appeared to correlate with the vancomycin MIC result, with reduced NF-kappaB activation detected with all the strains with a vancomycin MIC of 4 mg/L, but only with one of those with an MIC of 2 mg/L. To determine the biological impact of this effect, a single pair (JKD6021 and JKD6023) were selected to determine if the reduced NF-kappaB activation resulted in a diminished expression of the NF-kappaB-dependent inflammatory cytokines TNF-alpha and IL-1beta. As demonstrated in Figure 6, after 6 hours exposure to both strains, there was a significant decrease in TNF-alpha expression when comparing JKD6021 to JKD6023 (p < 0.001), while IL-1beta expression was substantially decreased.
###end p 40
###begin p 41
###xml 0 66 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NF-&#954;B activation results for VSSA and hVISA/VISA isolate pairs</bold>
###xml 339 341 331 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 33 37 <span type="species:ncbi:1280">VSSA</span>
###xml 48 52 <span type="species:ncbi:1280">VISA</span>
###xml 171 175 <span type="species:ncbi:1280">VSSA</span>
###xml 186 190 <span type="species:ncbi:1280">VISA</span>
###xml 271 275 <span type="species:ncbi:1280">VISA</span>
###xml 288 292 <span type="species:ncbi:1280">VSSA</span>
NF-kappaB activation results for VSSA and hVISA/VISA isolate pairs. Stably transfected RAW cells with an ELAM-NF-kB reporter construct were exposed to formaldehyde killed VSSA and hVISA/VISA pairs for 6 hours. Results are presented as fold NF-kappaB activation for hVISA/VISA compared to VSSA and are the result of multiple replicates. (* p < 0.05)
###end p 41
###begin p 42
###xml 0 33 0 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TNF-&#945; and IL-1&#946; expression</bold>
###xml 174 176 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 144 148 <span type="species:ncbi:1280">VSSA</span>
###xml 163 167 <span type="species:ncbi:1280">VISA</span>
TNF-alpha and IL-1beta expression. TNF-alpha and IL-1beta expression from RAW264.7 cells after 6 hours exposure to formaldehyde killed JKD6021 (VSSA) and JKD6023 (VISA). (** p < 0.001).
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 22 44 22 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1043 1047 1043 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1277 1286 1277 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 1487 1488 1487 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 1872 1882 1872 1882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 22 43 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 45 49 <span type="species:ncbi:1280">MRSA</span>
###xml 131 135 <span type="species:ncbi:1280">MRSA</span>
###xml 233 237 <span type="species:ncbi:1280">MRSA</span>
###xml 445 449 <span type="species:ncbi:1280">VSSA</span>
###xml 460 464 <span type="species:ncbi:1280">VISA</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 504 508 <span type="species:ncbi:1280">MRSA</span>
###xml 600 604 <span type="species:ncbi:1280">VISA</span>
###xml 636 640 <span type="species:ncbi:1280">VSSA</span>
###xml 767 771 <span type="species:ncbi:1280">VISA</span>
###xml 976 980 <span type="species:ncbi:1280">MRSA</span>
###xml 1277 1286 <span type="species:ncbi:1280">S. aureus</span>
###xml 1695 1703 <span type="species:ncbi:9606">patients</span>
###xml 1872 1881 <span type="species:ncbi:1280">S. aureus</span>
Methicillin-resistant Staphylococcus aureus (MRSA) is on the rise globally [26,27], with recent failures of vancomycin therapy for MRSA infections associated with low-level resistance to glycopeptides [3,28]. In addition, persistent MRSA bacteremia despite vancomycin therapy has also been recognized as an important clinical syndrome which is incompletely understood [29]. We have investigated transcriptional changes in five clinical pairs of VSSA and hVISA/VISA isolated from patients with persistent MRSA bacteremia on vancomycin therapy. Multiple gene expression changes were found in the hVISA/VISA strains compared to the parent VSSA, but essentially no changes were found in three control pairs of strains, suggesting the transcriptional changes in the hVISA/VISA strains are linked to resistance. Despite the different PFGE patterns [12], the five isolate pairs are closely related as determined by sequence based typing (by multi-locus sequence typing all are ST239-MRSA) [data not shown] and 4 of the 5 isolate pairs have identical spa types [12]). Although there were some consistent transcriptional changes found, there were very few consistent changes across all pairs, suggesting that multiple transcriptional pathways lead to low-level vancomycin resistance in S. aureus, and this is further supported by the detailed analysis of "cell wall stimulon" activation in our strains. These results are most clearly demonstrated by the global heat map analysis (additional file 3) that displays the major differences in the transcriptional patterns among the isolate pairs. In addition, we have demonstrated for the first time that the development of low-level vancomycin resistance in patients with persistent bacteraemia is associated with changes in the cell surface and alterations in the host immune response. These are important findings demonstrating that S. aureus strains evolve to alter immune system activation, in association with changes leading to reduced response to vancomycin therapy.
###end p 44
###begin p 45
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 495 505 495 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 530 536 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 843 853 843 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1062 1068 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 1103 1104 1103 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 41 45 <span type="species:ncbi:1280">VISA</span>
###xml 318 322 <span type="species:ncbi:1280">VISA</span>
###xml 495 504 <span type="species:ncbi:1280">S. aureus</span>
###xml 629 633 <span type="species:ncbi:1280">VISA</span>
###xml 804 808 <span type="species:ncbi:1280">VISA</span>
###xml 843 852 <span type="species:ncbi:1280">S. aureus</span>
###xml 1089 1093 <span type="species:ncbi:1280">VISA</span>
###xml 1199 1203 <span type="species:ncbi:1280">VISA</span>
A consistent theme from other studies of VISA strains has been the up-regulation of cell wall biosynthetic genes [14,15,18,21], including the vraSR two-component regulatory system and genes from this regulon. It is hypothesized that vancomycin activates the "cell wall stress stimulon" which then remains activated in VISA strains even after the vancomycin is removed. However, by examining multiple clinical isolates, we have established that low-level vancomycin resistance can be acquired in S. aureus without up-regulation of vraSR and other genes of the "cell wall stimulon". In fact, these genes were down-regulated in one VISA strain (JKD6023) in the initial analysis and in another strain (JKD6005) after vancomycin exposure. This is an important finding that clearly demonstrates that the hVISA/VISA phenotype can develop in clinical S. aureus isolates (associated with cell wall thickening and reduced autolytic activity [12]) without a sustained induction of the "cell wall stimulon". In addition, despite recent data suggesting that mutations in the vraSR operon are common in VISA strains [6], we found no mutations in this region in our strains. It is important to note that our hVISA/VISA isolates are all the same MLST type, and therefore are not from significantly different genetic backgrounds. This suggests that different pathways to resistance exist, even in genetically closely related strains, but that our results may not however apply to strains of other genetic backgrounds, such as Mu50 and Mu3.
###end p 45
###begin p 46
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 537 541 537 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 309 313 <span type="species:ncbi:1280">VISA</span>
###xml 690 694 <span type="species:ncbi:1280">VISA</span>
###xml 935 939 <span type="species:ncbi:1280">VISA</span>
Recent studies have highlighted some of the difficulties in interpreting microarray data without analysis of the effects the transcriptional changes on the expression of gene products [30]. We addressed this issue by quantitating a number of the gene products which were differentially expressed in the hVISA/VISA isolates. The microarray data was supported by protein A production, capsule expression and urease activity analysis. In addition, our previous real-time PCR analysis of RNAIII expression correlates well with the decreased agr expression found in the microarray analysis [12]. The increased capsule expression and reduced protein A production demonstrated in 4 of the 5 hVISA/VISA strains is of interest. These changes are likely to have significant implications for host pathogen interactions, and in fact, could favor persistent infection. For this reason, we performed experiments to determine the impact of the hVISA/VISA phenotype on immune system activation, as measured by NF-kappaB activation.
###end p 46
###begin p 47
###xml 331 332 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 767 769 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1286 1290 1256 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 53 57 <span type="species:ncbi:1280">VISA</span>
###xml 218 222 <span type="species:ncbi:1280">VISA</span>
###xml 350 354 <span type="species:ncbi:1280">VISA</span>
###xml 404 408 <span type="species:ncbi:1280">VSSA</span>
###xml 1065 1069 <span type="species:ncbi:1280">VISA</span>
###xml 1090 1094 <span type="species:ncbi:1280">VSSA</span>
###xml 1299 1303 <span type="species:ncbi:1280">VISA</span>
###xml 1458 1462 <span type="species:ncbi:1280">VISA</span>
We have clearly demonstrated that the development of VISA is associated with changes in NF-kappaB activation, which will affect the host pro-inflammatory response to infection. This was clearly demonstrated with the 3 VISA strains that had a vancomycin MIC of 4 mg/L, and one of the strains with a vancomycin MIC of 2 mg/L (Figure 5). Although hVISA/VISA strains may have slower growth rates compared to VSSA, we controlled for this in our NF-kappaB activation assays by growing cells to stationary phase and performing colony counts so that equivalent inoculums of killed cells were used in the assays. Many different staphylococcal components activate the innate immune system and induce NF-kappaB activation; including protein A, teichoic acids and peptidoglycan [31]. The activation of NF-kappaB in turn up-regulates the expression of pro-inflammatory cytokines including TNF-alpha and IL-1beta. The biological impact of this altered immune response was further highlighted by using the strain pair JKD6021 and JKD6023 which confirmed that RAW cells exposed to VISA strains compared to VSSA isolates display a reduced TNF-alpha and IL-1beta expression. Secreted exotoxins also activate innate immune responses, and although we did not measure these directly, the down-regulation of agr in hVISA/VISA strains, including our strains, would also limit immune activation by reducing exotoxin production. The cell surface changes we demonstrated in our hVISA/VISA isolates more closely associate to the altered host responses demonstrated here.
###end p 47
###begin p 48
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 476 480 476 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 684 688 684 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 108 112 <span type="species:ncbi:1280">VISA</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 225 229 <span type="species:ncbi:1280">MRSA</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
###xml 558 562 <span type="species:ncbi:1280">VISA</span>
###xml 739 743 <span type="species:ncbi:1280">MRSA</span>
Our results confirm the potential importance of changes in the agr two-component regulatory system in hVISA/VISA strains [32,33]. Recently, reduced agr function has been demonstrated in isolates from patients with persistent MRSA bacteraemia where vancomycin resistance was not demonstrated [29,34]. Although we have demonstrated reduced agr expression in a number of our strains previously by real time PCR [12] and now by microarray analysis, we did not find any changes in agr expression in isolates from patients with persistent bacteremia without hVISA/VISA. This suggests that there is a link between reduced agr expression and low-level vancomycin resistance, but that reduced agr expression is not always associated with prolonged MRSA bacteraemia and vancomycin therapy as previously suggested [29,34].
###end p 48
###begin p 49
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 562 571 562 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1054 1064 1054 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1328 1330 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1494 1496 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1769 1773 1769 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 1881 1885 1881 1885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 1929 1933 1929 1933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 1971 1973 1971 1973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2186 2195 2186 2195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 2208 2212 2208 2212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 71 75 <span type="species:ncbi:1280">VISA</span>
###xml 205 209 <span type="species:ncbi:1280">VISA</span>
###xml 288 292 <span type="species:ncbi:1280">VISA</span>
###xml 423 427 <span type="species:ncbi:1280">VISA</span>
###xml 599 604 <span type="species:ncbi:9606">human</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 1054 1063 <span type="species:ncbi:1280">S. aureus</span>
###xml 1733 1737 <span type="species:ncbi:1280">VISA</span>
###xml 1859 1863 <span type="species:ncbi:1280">VISA</span>
###xml 2065 2069 <span type="species:ncbi:1280">VISA</span>
###xml 2186 2195 <span type="species:ncbi:1280">S. aureus</span>
Although up-regulation of capsule genes has been demonstrated in other VISA strains [15,20] enhanced capsule production has never previously been confirmed. Loss of capsule typability has been reported in VISA revertant strains obtained by serial passage [35], and electron microscopy of VISA strain JH9 demonstrates what is probably excess capsule [11], however the potential importance of capsule expression in the hVISA/VISA phenotype has not been considered. Over-expression of staphylococcal capsular polysaccharide type 8 has been shown to protect against in vitro opsonophagocytic killing by human neutrophils and lead to more persistent blood stream and organ infection in mice [36]. Recently, up-regulation of capsule gene expression has been documented as part of the global transcriptional response that contributes to innate immune system evasion [37]. It is conceivable that the changes in capsule expression are an adaptation to allow the bacteria to persist in the blood stream and evade immune system killing. It has also been shown that S. aureus with increased capsule are less adherent to epithelial cell monolayers, and to damaged heart valves [38], and recently is has been determined that increased capsule expression blocks clumping factor A-mediated binding of staphylococci to fibrinogen and platelets [39]. Therefore the increased capsule changes we observed may play a role in the reduced biofilm formation that we have previously demonstrated in these same strains [12], possibly by masking important adhesins involved in the early stages of biofilm formation. It is also worth considering if the increased capsule production could directly contribute to the low-level vancomycin resistance in some hVISA/VISA strains, or interfere with the agr quorum sensing system, and explain the quorum sensing changes observed in these hVISA/VISA strains (reduced agr expression), especially as mutations in the agr operon were not found in the strains [12]. More work is needed to determine if increased capsule expression is common in many hVISA/VISA strains, and to understand the impact of capsule production on the expression of low-level vancomycin resistance in S. aureus, and on the agr system.
###end p 49
###begin p 50
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 544 553 540 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 650 652 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 797 799 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 843 845 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 986 988 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 989 991 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1068 1070 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1097 1107 1093 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 1296 1298 1292 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1299 1301 1295 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1570 1572 1562 1564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1621 1623 1610 1612 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1724 1726 1713 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1742 1746 1731 1735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 1863 1867 1852 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 92 96 <span type="species:ncbi:1280">VISA</span>
###xml 247 251 <span type="species:ncbi:1280">VISA</span>
###xml 544 553 <span type="species:ncbi:1280">S. aureus</span>
###xml 1097 1106 <span type="species:ncbi:1280">S. aureus</span>
###xml 1232 1236 <span type="species:ncbi:1280">VISA</span>
###xml 1367 1371 <span type="species:ncbi:1280">VISA</span>
###xml 1711 1716 <span type="species:ncbi:9606">human</span>
Down-regulation of spa is one of the most consistent transcriptional changes found in hVISA/VISA strains [14,15,17,33,40]. We have shown by western blot that reduced spa expression leads to almost complete absence of protein A expression in hVISA/VISA strains. In addition, consistent down-regulation of the gene encoding another IgG-binding protein (Sbi) was also found. These changes are likely to have significant biological implications, and could partly explain the changes in NF-kappaB activation. Protein A is a major surface protein of S. aureus. It binds to the Fc region of IgG, and the Fab portion of Ig belonging to the VH3+ gene family [41] where it may act as a B cell superantigen, but also binds to several other proteins including gC1qR which is expressed on activated platelets [41]. Protein A triggers platelet aggregation [42], and along with other staphylococcal surface proteins (such as fibronectin binding proteins [FnBPs]) has been shown to activate platelets [43,44]. Upon activation platelets release platelet microbiocidal proteins (PMPs) [45]. The interaction between S. aureus and platelets, and in particular the role of PMPs in protection against intravascular infections, and the link between hVISA/VISA and reduced susceptibility to PMP has been well described [29,32]. The decreased protein A and FnBPs expression seen in our hVISA/VISA strains would be expected to lead to less platelet activation. Recently, protein A has also been shown to activate a respiratory epithelial inflammatory response by binding to TNR-alpha receptor 1 [46]. Staphylococcal protein Sbi is an IgG- and beta2 glycoprotein I-binding protein that has been found to be up-regulated after exposure to human serum [47]. Decreases in spa expression were not seen in the 3 control pairs of strains. Nonetheless, along with increased capsule expression the spa changes have the potential to alter immune system response to infection and promote persistent infection.
###end p 50
###begin p 51
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 504 514 504 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 57 61 <span type="species:ncbi:1280">VISA</span>
###xml 233 237 <span type="species:ncbi:1280">VISA</span>
###xml 504 513 <span type="species:ncbi:1280">S. aureus</span>
###xml 702 706 <span type="species:ncbi:1280">VISA</span>
###xml 798 802 <span type="species:ncbi:1280">VISA</span>
Increased urease activity has not been reported in hVISA/VISA strains. Urease is involved in the urea cycle and amino acid metabolism as well as purine metabolism [48]. The reasons for the increased production of urease in our hVISA/VISA strains is not clear, but may be linked to increased amino acid biosynthesis, with increased expression of genes involved in aspartate biosynthesis in particular found in the microarray analysis. Recently, up-regulation of urease production has been demonstrated in S. aureus biofilms, and it was hypothesized that increased ammonium and/or ammonia is required to counteract the acid environment in the biofilm. It is not clear how this may be linked to the hVISA/VISA phenotype, except that increased energy requirements and increased metabolism in the hVISA/VISA cell may require increased urease activity.
###end p 51
###begin p 52
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR</italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">saeSR</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mrgA </italic>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rot</italic>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 833 843 833 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 372 376 <span type="species:ncbi:1280">VISA</span>
###xml 585 589 <span type="species:ncbi:1280">VSSA</span>
###xml 600 604 <span type="species:ncbi:1280">VISA</span>
###xml 833 842 <span type="species:ncbi:1280">S. aureus</span>
Sequencing of a number of regulatory genes that were differentially expressed in the microarray analysis (vraSR, saeSR, SACOL2193, SACOL2517) or were potentially involved in the changes we found (mrgA and rot) revealed no nucleotide changes. However, any mutations associated with resistance in these strains are clearly leading to global transcriptional changes in hVISA/VISA isolates. The recent work by Mwangi et al [6] demonstrated that a small number of mutations could lead to an increase in vancomycin MIC up to 4 mg/L in the strain they studied. In our previous study of these VSSA and hVISA/VISA clinical isolates we demonstrated by PFGE a difference in banding patterns for the pairs JKD6000/JKD6001 and JKD6021/JKD6023 [12]. A genomic microarray comparison using the whole genome of MRSACOL and selected unique genes from S. aureus strains Mu50, MW2 and N315 (TIGR version 2 array) failed to reveal any genetic changes in these pairs [12]. Because the aims of this study were to determine transcriptional changes using the TIGR ver2 arrays, we have not been able to provide any further explanation for the difference in PFGE banding patterns. It is possible that loss of phage DNA could explain the changes, and is unlikely to contribute to the resistance phenotype, but confirmation would require a whole genome comparison.
###end p 52
###begin title 53
Conclusion
###end title 53
###begin p 54
###xml 56 66 56 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR </italic>
###xml 23 27 <span type="species:ncbi:1280">VISA</span>
###xml 56 65 <span type="species:ncbi:1280">S. aureus</span>
###xml 279 283 <span type="species:ncbi:1280">VISA</span>
###xml 408 412 <span type="species:ncbi:1280">VISA</span>
###xml 615 619 <span type="species:ncbi:1280">VISA</span>
The emergence of hVISA/VISA from vancomycin-susceptible S. aureus can occur by different transcriptional pathways, even in closely related strains, and it appears that up-regulation of the "cell wall stimulon" and mutations in vraSR are not essential for the generation of hVISA/VISA. Changes in capsule production and protein A expression frequently accompany the altered antibiotic susceptibility in hVISA/VISA strains, and reduced innate immune activation may be another factor promoting persistence of infection. Further work is required to fully understand the impact of changes in immune recognition of hVISA/VISA strains. Identifying the mutation or mutations leading to resistance in our strains will require a global comparative genomics approach.
###end p 54
###begin title 55
Methods
###end title 55
###begin title 56
Bacterial strains, antibiotic susceptibility and molecular typing
###end title 56
###begin p 57
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 140 150 140 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 712 716 712 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spa </italic>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 140 149 <span type="species:ncbi:1280">S. aureus</span>
###xml 305 309 <span type="species:ncbi:1280">VSSA</span>
###xml 320 324 <span type="species:ncbi:1280">VISA</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 438 442 <span type="species:ncbi:1280">VISA</span>
Staphylococcus aureus strains are listed in table 1. All strains were clinical isolates from patients with persistent methicillin-resistant S. aureus bacteraemia (blood culture positive after > 7 days of vancomycin therapy) [12]. Isolate pairs 1 to 5 have been previously well characterized and represent VSSA and hVISA/VISA pairs [12]. Isolate pairs 6 to 8 are blood culture isolates (patients with bacteremia for 8-22 days) where hVISA/VISA was not detected in the later clinical isolate. All isolates were grown in brain heart infusion broth (BHIB) (Oxoid). For the control pairs vancomycin population analysis profile (PAP), vancomycin and teicoplanin broth minimum inhibitory concentrations (MIC), PFGE and spa typing were performed as previously described [12].
###end p 57
###begin title 58
Preparation of total RNA
###end title 58
###begin p 59
###xml 209 214 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">later</italic>
###xml 329 331 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
After overnight growth in BHIB a 1 in 100 dilution was made in 50 ml of BHIB and incubated at 37degreesC with shaking. Exponential-phase culture (20 ml) was added to 10 ml of an RNA stabilization reagent (RNA later, Qiagen) and allowed to stand for 10 min after mixing. Total RNA was prepared using the RNeasy Midi Kit (Qiagen) [12]. For vancomycin experiments, vancomycin (Sigma) was added to cultures in early exponential growth (final concentration 0.5 x MIC) for 30 min before RNA extraction.
###end p 59
###begin title 60
Preparation of Cy3- and Cy5-dUTP labeled cDNA probe
###end title 60
###begin p 61
###xml 63 67 <span type="species:ncbi:1280">VISA</span>
###xml 92 96 <span type="species:ncbi:1280">VSSA</span>
###xml 156 160 <span type="species:ncbi:1280">VSSA</span>
###xml 251 255 <span type="species:ncbi:1280">VSSA</span>
###xml 266 270 <span type="species:ncbi:1280">VISA</span>
Transcription profiling to compare the later clinical isolate (VISA/hVISA for pairs 1 to 5, VSSA for pairs 6 to 8) to the related initial clinical isolate (VSSA) was performed for each pair without antibiotics, and repeated after exposure of both the VSSA and hVISA/VISA isolates to vancomycin for pairs 1 to 5. cDNA was synthesized using SuperScripttrade mark II RNase H-Reverse Transcriptase (Invitrogen) incorporating aminoallyl-dUTP at 42degreesC with the following reaction mixture (RNA 5 mug, random hexamers 6 mug, Superscript II RT 400 U, 0.5 mM dATP, dCTP, dGTP, 0.2 mM dTTP, 0.3 mM aa-dUTP [Amersham Biosciences]; total volume 30.7 mul). The RNA was hydrolyzed by addition of 10 mul 0.5 M EDTA and 10 mul 1 M NaOH with incubation at 65degreesC for 15 min, followed by addition of 25 mul 1 M Tris (pH 7.0) to neutralize the pH. The cDNA was collected using a QIAquick column (Qiagen) and dried to completion in a vacuum concentrator. The aminoallyl-labeled cDNA was resuspended in 4.5 mul 0.1 M sodium bicarbonate buffer (pH 9.3) and incubated at room temperature for 2 hours after addition of Cy3 or Cy5 (Amersham Biosciences) resuspended in 4.5 mul DMSO (Sigma). The probe was purified using a microcon-30 column. The quantity of cDNA and incorporation ratio of Cy dye was measured by spectrophotometry (NanoDrop ND-1000, NanoDrop Technologies, DE, USA) to confirm acceptable results and then the two differentially labeled probes were mixed and dried to completion in a vacuum concentrator.
###end p 61
###begin title 62
Array hybridization and analysis
###end title 62
###begin p 63
###xml 58 80 58 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 58 79 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Array hybridization, washing and scanning using version 2 Staphylococcus aureus microarray slides (The Institute for Genomic Research, MD, USA) was performed as described previously [12]. Briefly, 30 mul of hybridization mixture containing Cy3- and Cy5-dUTP labeled probe, 15 mul formamide (Sigma), 5 x SSC, 0.1% SDS, and 22.5 mug herring sperm DNA (Promega) was denatured at 95degreesC then applied to the microarray slide and incubated overnight at 42degreesC. The microarray was washed sequentially in 2 x SSC, 0.1% SDS; 0.1 x SSC, 0.1% SDS; and 0.1 x SSC and then dried. The microarrays were scanned with the GMS418 Array scanner (Genetic MicroSystems) to measure the fluorescence of the Cy3 and Cy5 labeled cDNA hybridized to the microarray. The images were combined and quantification of fluorescent and background intensity determined using ImaGenetrade mark ver 5.1 (Biodiscovery).
###end p 63
###begin p 64
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 964 966 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 449 453 <span type="species:ncbi:1280">VISA</span>
###xml 514 518 <span type="species:ncbi:1280">VSSA</span>
###xml 737 741 <span type="species:ncbi:1280">VISA</span>
RNA extraction and hybridizations were performed in triplicate, and the dye swapped with each replicate. Using BASE [49] the data from the three biological replicates were combined and analyzed using Bioconductor and in particular Limma [50]. After global lowess normalization the log-ratios for each array were scaled so that the median absolute deviation was the same between arrays. For each gene ID a fold ratio of later clinical isolate (hVISA/VISA for pairs 1 to 5) compared to the earlier clinical isolate (VSSA) was calculated. Using a moderated t-test P-values were calculated and adjusted for multiple testing using false-discovery-rate (FDR). A >/= 1.5-fold change and P value < 0.05 was considered significant. For the hVISA/VISA comparison any genes which were consistently up or down regulated across at least two clinical pairs was included in the set of "genes of interest". Heat maps of the normalized microarray results were generated using MeV [51].
###end p 64
###begin title 65
Protein Extraction
###end title 65
###begin p 66
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 489 492 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 526 529 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
Cell wall associated proteins for protein A quantification were extracted as previously described [52]. Isolates were grown in BHIB in an identical manner as described for RNA extractions. Thirty ml of exponential stage culture was placed in a falcon tube and centrifuged at 5000 x g for 10 min. After removal of the supernatant 600 mul of extraction buffer (30% raffinose in 0.05 M Tris [pH 7.5] with 0.145 M NaCl) containing lysostaphin (Sigma) (250 ug), 10 mug of DNase (Sigma), 1 mg ml-1 iodoacetamide (Sigma), and 1 mM ml-1 phenylmethylsulfonyl fluoride (Sigma) was added. The mixture was incubated for 1 h at 37degreesC with rotation and then centrifuged at 8000 x g for 10 min, and the supernatant was centrifuged at 8000 x g for a further 10 min. Cellular protein for assessment of urease activity was extracted from eight ml of culture. The culture was pelleted, washed in PBS at 4degreesC, and resuspended in 1 ml PBS (4degreesC). The cells were disrupted in a FastPreptrade mark FP120 (Bio101 Savant, CA, USA) (setting 6 for 45 sec x 2) and the tube was centrifuged at 12,000 x g for 30 min at 4degreesC. The supernatant was transferred to a new tube. Protein concentrations were measured using the BCA protein assay kit (Pierce, IL, USA) and stored in aliquots at -80degreesC.
###end p 66
###begin title 67
SDS-PAGE and western blot analysis for protein A expression
###end title 67
###begin p 68
###xml 92 94 91 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
###xml 324 329 <span type="species:ncbi:9940">sheep</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
Fifteen mug of cell wall associated protein from each isolate was separated in a 12% (wt vol-1) SDS-PAGE gel. The protein samples were transferred from the SDS-PAGE gel to cellulose nitrate transfer membrane (Schleicher & Schuell). A mouse derived monoclonal anti-protein A antibody (2000 x dilution) (Sigma), and secondary sheep anti-mouse IgG peroxidase conjugate (2000 x dilution) (Silenus) were used. The blots were developed using the Western Lightening chemiluminescence kit (Perkin-Elmer) and the image acquired and analyzed using the LAS-3000 Luminescent Image Analysis System (Fujifilm, Tokyo, Japan) and Multi Gauge version 2.2 software (Fujifilm, Tokyo, Japan).
###end p 68
###begin title 69
Urease Assays
###end title 69
###begin p 70
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 485 488 482 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 501 503 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
Urease activity was measured using a coupled enzyme assay [53]. The 1.5 ml reaction mixture contained 31 mM Tris-HCl (pH 8.0), 10 mM urea (Amresco, OH, USA), 810 muM 2-oxoglutarate (Sigma), 240 muM NADH and 1.34 mg glutamate dehydrogenase (Sigma). Reactions were performed at room temperature and NADH degradation was measured by absorbance at 340 nM using a 552 UV-VIS spectrophotometer (Perkin-Elmer). The urease activity of each isolate was expressed as mumol of urea hydrolyzed min-1 mg of protein-1.
###end p 70
###begin title 71
Capsule typing and Quantification
###end title 71
###begin p 72
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 535 537 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 732 735 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 771 774 757 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 821 824 806 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 1044 1050 <span type="species:ncbi:9986">rabbit</span>
###xml 1099 1104 <span type="species:ncbi:9940">sheep</span>
###xml 1110 1116 <span type="species:ncbi:9986">rabbit</span>
A multiplex PCR for capsule genotyping (CP5 and CP8) was designed using sequences available in NCBI (accession numbers for cap5, U811973; cap8, U73374). The forward primer was in Cap5/8G and the reverse primers in the variable regions, Cap5H and Cap8H (Table 3). The CP8 positive strain P1 and the CP5 positive strain Newman were used as controls. For capsule quantification a capsule immunoblot was performed [36]. Crude capsule extracts were prepared after growth in BHIB for 18 h at 37degreesC, using a previously described method [54]. After adjusting the OD600 to 0.5, 10 ml of culture was pelleted, resuspended in 500 mul PBS, then treated with the following enzymes consecutively at 37degreesC; lysostaphin (sigma) 200 mug ml-1 for 15 min; DNase I (sigma) 300 U ml-1 for 15 min; and proteinase K (sigma) 100 mug ml-1 for 1 h, and then inactivated at 75degreesC for 10 min. Serial dilutions were loaded onto nitrocellulose membrane using a dot-blot apparatus. After blocking with 5% skim milk the membrane was incubated with CP8-specific rabbit antiserum kindly provided by Jean Lee, and then sheep anti-rabbit IgG peroxidase conjugate (Chemicon, Australia). The blots were developed as described above.
###end p 72
###begin p 73
Primers used in study
###end p 73
###begin title 74
DNA techniques
###end title 74
###begin p 75
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 396 408 396 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vraSR, saeSR</italic>
###xml 410 413 410 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rot</italic>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mgrA </italic>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 500 504 <span type="species:ncbi:1280">MRSA</span>
Genomic DNA was extracted using the GenElute Bacterial Genomic DNA Kit (Sigma). PCR was carried out using Taq DNA polymerase (Roche Molecular Biochemicals). DNA sequencing was performed using the BigDye Terminator version 3.1 cycle sequencing kits (Applied Biosystems) and the reaction mixtures were analyzed with the 3730 DNA Analyser (Applied Biosystems). Primers for amplifying and sequencing vraSR, saeSR, rot, SACOL2193 and SACOL2517, MW2406 to MW2407, and mgrA (SA0641) were designed using the MRSA COL, MW2 and N315 genome sequences (Table 3).
###end p 75
###begin title 76
NF-kappaB assay
###end title 76
###begin p 77
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 502 504 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 534 536 530 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 740 741 729 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 875 876 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1060 1063 1041 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink">96 </sub>
###xml 1254 1256 1234 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 391 396 <span type="species:ncbi:10090">mouse</span>
###xml 775 779 <span type="species:ncbi:1280">VSSA</span>
###xml 789 793 <span type="species:ncbi:1280">VISA</span>
Staphylococcus aureus cells were prepared from stationary phase cultures by washing in cold PBS and resuspending in 5% formaldehyde for 1 h, followed by additional washes in PBS. Colony counts were performed prior to the addition of formaldehyde, to allow inoculation of equivalent cell numbers in the stimulation assays. Three biological replicates were prepared for each isolate. RAW264.7 mouse macrophage cells stably expressing the NF-kappaB-dependent ELAM-luciferase reporter construct were used [55]. Cells were seeded at 2 x 104 cells/well of a 96-well flat bottomed tissue culture plate in 100 mul LPS-free media (RPMI plus 0.5 mg/ml G418, supplemented with 10% FCS and 1 mM L-glutamine) and incubated overnight at 37degreesC, 5% CO2. Cells were then stimulated with VSSA or hVISA/VISA isolates in triplicate, at a range of concentrations for 6 h at 37degreesC, 5% CO2. After removing the media 50 mul of 1 x Promega passive lysis buffer was added to each well (5 min at room temperature). Twenty mul from each well was transferred to a white opaque TC96 plate, and 30 mul Luciferase assay reagent (Promega) added. Luciferase activity was measured with a Fluro-Optima luminometer. The statistical significance of the data was evaluated by paired t test using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA).
###end p 77
###begin title 78
TNF-alpha and IL-1beta immunoassays
###end title 78
###begin p 79
###xml 201 203 194 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 386 387 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 477 478 457 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 643 645 617 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 49 54 <span type="species:ncbi:10090">Mouse</span>
###xml 421 425 <span type="species:ncbi:1280">VSSA</span>
###xml 430 434 <span type="species:ncbi:1280">VISA</span>
These assays were performed using the Quantikine Mouse TNF-alpha and IL-1beta immunoassay kits (R&D Systems) according to the manufacturers' instructions. Briefly, RAW 264.7 cells were seeded at 2 x 104 cells/well of a 96-well flat bottomed tissue culture plate in 100 mul LPS-free media (RPMI supplemented with 10% FCS and 1 mM L-glutamine) and incubated overnight at 37degreesC, 5% CO2. Cells were then stimulated with VSSA and VISA in triplicate for 6 h at 37degreesC, 5% CO2. After spinning the plates supernatant from each well was stored at -20degreesC prior to analysis. The statistical significance of the data was evaluated by paired t test using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA)
###end p 79
###begin title 80
Authors' contributions
###end title 80
###begin p 81
BH carried out all the experimental work, except for the assay to assess innate immune responses which were performed by DS. The study was conceived by JD, PJ, BH and AM. PW carried out initial characterization of the strains used in the study. PJ assisted with statistical analysis and TS assisted with assessment of sequencing results. AM, JD and TS assisted BH with drafting the manuscript. All authors read and approved the final manuscript.
###end p 81
###begin title 82
Supplementary Material
###end title 82
###begin title 83
Additional file 1
###end title 83
###begin p 84
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Complete figure </bold>
###xml 16 17 16 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Complete figure 1. Full image of heat map analysis of selected genes which were differentially expressed in at least 2 isolate pairs.
###end p 84
###begin p 85
Click here for file
###end p 85
###begin title 86
Additional file 2
###end title 86
###begin p 87
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Data table </bold>
###xml 11 12 11 12 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1a</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1b</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1c</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1d</xref>
###xml 58 62 <span type="species:ncbi:1280">VISA</span>
###xml 66 70 <span type="species:ncbi:1280">VSSA</span>
###xml 268 272 <span type="species:ncbi:1280">VISA</span>
###xml 276 280 <span type="species:ncbi:1280">VSSA</span>
Data table 1. Summary of microarray results for the hVISA/VISA to VSSA comparison. Any genes which were consistently up or down regulated across at least two clinical pairs were included in the set of "genes of interest". Data are presented as the fold ratio of hVISA/VISA to VSSA. Table 1a and 1b are without vancomycin exposure. Table 1c and 1d are after vancomycin exposure (see methods section for details).
###end p 87
###begin p 88
Click here for file
###end p 88
###begin title 89
Additional file 3
###end title 89
###begin p 90
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Global heat map</bold>
###xml 137 141 <span type="species:ncbi:1280">VISA</span>
###xml 154 158 <span type="species:ncbi:1280">VSSA</span>
Global heat map. Heat map analysis for all genes on the microarray. The results are expressed as fold ratio of gene expression for hVISA/VISA compared to VSSA. Results are presented for all 5 isolate pairs without antibiotic exposure and all 5 isolate pairs after exposure to vancomycin.
###end p 90
###begin p 91
Click here for file
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
Benjamin Howden was supported by a Postgraduate Medical and Dental Scholarship from the National Health and Medical Research Council, Australia.
###end p 93
###begin p 94
This work was supported by The Australian Bacterial Pathogenesis Program from the National Health and Medical Research Council, and the Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics, Australia.
###end p 94
###begin p 95
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Staphylococcus aureus microarray slides were kindly supplied by The Institute for Genomic Research (TIGR), Rockville, MD.
###end p 95
###begin p 96
###xml 31 36 <span type="species:ncbi:9606">Women</span>
###xml 92 99 <span type="species:ncbi:15957">Timothy</span>
We thank Jean Lee, Brigham and Women's Hospital, Boston for providing capsule antibody, and Timothy Foster, Trinity College, Dublin for supplying control strains.
###end p 96
###begin p 97
We also thank members of the Monash Infection and Immunity Network for their assistance.
###end p 97
###begin article-title 98
Vancomycin-resistant staphylococci and enterococci: epidemiology and control
###end article-title 98
###begin article-title 99
###xml 74 96 74 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 74 95 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility
###end article-title 99
###begin article-title 100
###xml 35 57 35 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 35 56 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Low-level vancomycin resistance in Staphylococcus aureus - an Australian perspective
###end article-title 100
###begin article-title 101
###xml 58 79 58 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 58 79 <span type="species:ncbi:1280">Staphylococcus aureus</span>
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus
###end article-title 101
###begin article-title 102
###xml 21 42 21 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 21 42 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
###end article-title 102
###begin article-title 103
###xml 58 80 58 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 58 79 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing
###end article-title 103
###begin article-title 104
###xml 69 90 69 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 69 90 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus
###end article-title 104
###begin article-title 105
###xml 58 80 58 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 58 79 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds
###end article-title 105
###begin article-title 106
###xml 54 76 54 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 54 75 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin
###end article-title 106
###begin article-title 107
###xml 120 142 120 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 120 141 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50
###end article-title 107
###begin article-title 108
###xml 143 164 143 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 143 164 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus
###end article-title 108
###begin article-title 109
###xml 95 117 95 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 95 116 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia
###end article-title 109
###begin article-title 110
###xml 80 101 80 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 80 101 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus
###end article-title 110
###begin article-title 111
###xml 75 97 75 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 75 96 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridisation method
###end article-title 111
###begin article-title 112
###xml 74 96 74 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 131 140 131 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 74 95 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 131 140 <span type="species:ncbi:1280">S. aureus</span>
Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin intermediate-S. aureus-type resistance to vancomycin
###end article-title 112
###begin article-title 113
###xml 57 79 57 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 57 78 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon
###end article-title 113
###begin article-title 114
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 42 63 <span type="species:ncbi:1280">Staphylococcus aureus</span>
In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance
###end article-title 114
###begin article-title 115
###xml 100 121 100 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 100 121 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus
###end article-title 115
###begin article-title 116
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr</italic>
###xml 63 85 63 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 63 84 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin
###end article-title 116
###begin article-title 117
###xml 88 109 88 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 88 109 <span type="species:ncbi:1280">Staphylococcus aureus</span>
DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus
###end article-title 117
###begin article-title 118
###xml 37 58 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers
###end article-title 118
###begin article-title 119
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mgrA </italic>
###xml 47 68 47 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 47 68 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Transcription Profiling of the mgrA Regulon in Staphylococcus aureus
###end article-title 119
###begin article-title 120
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aur</italic>
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sspA</italic>
###xml 101 123 101 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sarA</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rot </italic>
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 101 122 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Coordinated and differential control of aureolysin (aur) and serine protease (sspA) transcription in Staphylococcus aureus by sarA, rot and agr (RNAIII)
###end article-title 120
###begin article-title 121
Inhibition of rot translation by RNAIII, a key feature of agr function
###end article-title 121
###begin article-title 122
###xml 21 43 21 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rot</italic>
###xml 21 42 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Global regulation of Staphylococcus aureus genes by Rot
###end article-title 122
###begin article-title 123
###xml 86 108 86 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 86 107 <span type="species:ncbi:1280">Staphylococcus aureus</span>
An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states
###end article-title 123
###begin article-title 124
###xml 22 44 22 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 22 43 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002
###end article-title 124
###begin article-title 125
###xml 66 87 66 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 66 87 <span type="species:ncbi:1280">Staphylococcus aureus</span>
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
###end article-title 125
###begin article-title 126
###xml 51 73 51 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 51 72 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein
###end article-title 126
###begin article-title 127
###xml 78 99 78 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 78 99 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation
###end article-title 127
###begin article-title 128
###xml 15 36 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Recognition of Staphylococcus aureus by the innate immune system
###end article-title 128
###begin article-title 129
###xml 26 48 26 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 170 173 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr</italic>
###xml 26 47 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function
###end article-title 129
###begin article-title 130
###xml 126 147 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin resistant Staphylococcus aureus
###end article-title 130
###begin article-title 131
###xml 72 94 72 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 72 93 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 95 99 <span type="species:ncbi:1280">MRSA</span>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia
###end article-title 131
###begin article-title 132
###xml 54 76 54 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 54 75 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates
###end article-title 132
###begin article-title 133
###xml 14 36 14 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">agr </italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sarA</italic>
###xml 14 35 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA
###end article-title 133
###begin article-title 134
###xml 33 54 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils
###end article-title 134
###begin article-title 135
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Staphylococcus aureus capsular polysaccharides
###end article-title 135
###begin article-title 136
###xml 70 92 70 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 70 91 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Capsular Polysaccharide Masks Clumping Factor A-Mediated Adherence of Staphylococcus aureus to Fibrinogen and Platelets
###end article-title 136
###begin article-title 137
###xml 62 83 62 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 62 83 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Strain dependence of the cell wall-damage induced stimulon in Staphylococcus aureus
###end article-title 137
###begin article-title 138
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets
###end article-title 138
###begin article-title 139
Complement-dependent platelet injury by staphylococcal protein A
###end article-title 139
###begin article-title 140
###xml 72 93 72 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 72 93 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A
###end article-title 140
###begin article-title 141
The interaction of bacterial pathogens with platelets
###end article-title 141
###begin article-title 142
Antimicrobial peptides from platelets
###end article-title 142
###begin article-title 143
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1
###end article-title 143
###begin article-title 144
###xml 55 60 <span type="species:ncbi:9606">human</span>
Expression of staphylococcal protein Sbi is induced by human IgG
###end article-title 144
###begin article-title 145
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 42 63 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions
###end article-title 145
###begin article-title 146
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data
###end article-title 146
###begin article-title 147
Linear models and empirical Bayes methods for assessing differential expression in microarray experiments
###end article-title 147
###begin article-title 148
TM4: a free, open-source system for microarray data management and analysis
###end article-title 148
###begin article-title 149
###xml 53 75 53 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 53 74 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Variation in the expression of cell wall proteins of Staphylococcus aureus grown on solid and liquid media
###end article-title 149
###begin article-title 150
###xml 49 68 49 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori</italic>
###xml 49 68 <span type="species:ncbi:210">Helicobacter pylori</span>
Purification and characterization of urease from Helicobacter pylori
###end article-title 150
###begin article-title 151
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mgr</italic>
###xml 33 54 33 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 33 54 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Mgr, a novel global regulator in Staphylococcus aureus
###end article-title 151
###begin article-title 152
Macrophages Exposed Continuously to Lipopolysaccharide and Other Agonists that Act via Toll-Like Receptors Exhibit a Sustained and Additive Activation Rate
###end article-title 152
###begin article-title 153
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">murF</italic>
###xml 66 87 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Extensive and genome-wide changes in the transcription profile of Staphylococcus aureus induced by modulating the transcription of the cell wall synthesis gene murF
###end article-title 153
###begin article-title 154
###xml 38 59 38 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 38 59 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Genetic analysis of the cap5 locus of Staphylococcus aureus
###end article-title 154

